Hypoxia is a strong modulator of angiogenesis, accelerating adipose tissue expansion, suggesting that hypoxia inducible factor 1alpha (HIF1alpha) can be a novel target for anti-obesity. We conjugated antisense-HIF1alpha-oligonucleotide (ASO) with low molecular weight protamine (LMWP), a cell-penetrating peptide, to enhance its ability to block hypoxic-angiogenesis, thereby eliciting an anti-obesity effect. Nano-sized ASO-LMWP (AS-L) conjugates enhanced cellular uptake of ASO without yielding a cytotoxic effect and protected the ASO against enzymatic attack and chemical reduction. AS-L showed enhanced intra-cellular localization compared to naked ASO and the complex of ASO with lipofectamine during hypoxic-differentiation. Consequently AS-L induced significant down-regulation of leptin and VEGF gene expressions, thereby reducing fat accumulation in the cell. This proof-of-concept study shows that AS-L produces an inhibitory effect on adipogenesis and angiogenesis during differentiation, indicating LMWP mediated ASO delivery can potentially be a safe and promising treatment for obesity. Copyright 2010 Elsevier B.V. All rights reserved.
Hypoxia is a strong modulator of anpan>giogenesis, accelerating pan> class="Gene">adipose tissue expansion, suggesting that hypoxia inducible factor 1alpha (HIF1alpha) can be a novel target for anti-obesity. We conjugated antisense-HIF1alpha-oligonucleotide (ASO) with low molecular weight protamine (LMWP), a cell-penetrating peptide, to enhance its ability to block hypoxic-angiogenesis, thereby eliciting an anti-obesity effect. Nano-sized ASO-LMWP (AS-L) conjugates enhanced cellular uptake of ASO without yielding a cytotoxic effect and protected the ASO against enzymatic attack and chemical reduction. AS-L showed enhanced intra-cellular localization compared to naked ASO and the complex of ASO with lipofectamine during hypoxic-differentiation. Consequently AS-L induced significant down-regulation of leptin and VEGF gene expressions, thereby reducing fat accumulation in the cell. This proof-of-concept study shows that AS-L produces an inhibitory effect on adipogenesis and angiogenesis during differentiation, indicating LMWP mediated ASO delivery can potentially be a safe and promising treatment for obesity. Copyright 2010 Elsevier B.V. All rights reserved.
Authors: M A Rosenfeld; W Siegfried; K Yoshimura; K Yoneyama; M Fukayama; L E Stier; P K Pääkkö; P Gilardi; L D Stratford-Perricaudet; M Perricaudet Journal: Science Date: 1991-04-19 Impact factor: 47.728
Authors: M R Bishop; P L Iversen; E Bayever; J G Sharp; T C Greiner; B L Copple; R Ruddon; G Zon; J Spinolo; M Arneson; J O Armitage; A Kessinger Journal: J Clin Oncol Date: 1996-04 Impact factor: 44.544
Authors: C A Stein; J Bo Hansen; Johnathan Lai; SiJian Wu; Anatoliy Voskresenskiy; Anja Høg; Jesper Worm; Maj Hedtjärn; Naira Souleimanian; Paul Miller; Harris S Soifer; Daniella Castanotto; Luba Benimetskaya; Henrik Ørum; Troels Koch Journal: Nucleic Acids Res Date: 2009-10-23 Impact factor: 16.971
Authors: Tien-Yi Lee; Yoon Shin Park; George A Garcia; Roger K Sunahara; James H Woods; Victor C Yang Journal: Mol Pharm Date: 2012-03-28 Impact factor: 4.939
Authors: Yoon Shin Park; Allan E David; Yongzhuo Huang; Jun-Beom Park; Huining He; Youngro Byun; Victor C Yang Journal: J Control Release Date: 2012-04-23 Impact factor: 9.776
Authors: Meong Cheol Shin; Jian Zhang; Allan E David; Wolfgang E Trommer; Young Min Kwon; Kyoung Ah Min; Jin H Kim; Victor C Yang Journal: J Control Release Date: 2013-08-23 Impact factor: 9.776